Compare Natera Inc. Common Stock (NTRA) vs Rio Tinto (ADR) (RIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Rio Tinto (ADR) — how do they compare? Natera Inc. Common Stock trades at $386.99 (market cap $57.03B), while Rio Tinto (ADR) trades at $88.72 (market cap $149.24B). The key difference: Rio Tinto (ADR) is far larger — about 2.6× Natera Inc. Common Stock's market cap, and Rio Tinto (ADR) pays a 5.1% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Rio Tinto (ADR) for 12 Days on average.
| NTRA | RIO | |
|---|---|---|
Market Cap | $57.03B | $149.24B |
Volume | 1,131,157 | 2,122,105 |
Sector | Health | Basic Materials |
52-Week High | $425.64 | $112.04 |
52-Week Low | $179.42 | $67.89 |
Typical Hold Time | 0 Days | 12 Days |
Enterprise Value | $56.18B | $162.59B |
Dividend Yield | — | 5.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Rio Tinto (RIO) trades at $93.06, down 1.31% on the day, with mixed technical signals showing bearish moving averages but neutral oscillators. Fundamentally, the company demonstrates strong profitability with 19.58% net income margin and 19.57% ROE, supported by recent quarterly earnings beats. Recent news highlights operational strength with 27% copper production growth at Oyu Tolgoi and maintained 2026 guidance.
The stock presents a compelling value opportunity with a 12.61 P/E ratio trading below the $103.13 consensus target. However, bearish technical momentum and legal risks from Madagascar contamination claims warrant caution. Analyst sentiment is mixed with 35% buy ratings versus 23% sell recommendations, suggesting balanced risk-reward for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Rio Tinto (ADR)
Rio Tinto is a global mining company that produces metals and minerals including iron ore, aluminium, copper, and lithium. Its operations supply materials used in construction, manufacturing, transportation, and energy systems.
Read more on RIO →
